An Open Label, Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP( Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain.
Completed
Mallinckrodt
Phase 4
2014-05-01
The purpose of this study is to compare the analgesic efficacy of Xartemis 15mg/650mg by
mouth every 12 hours for the management of acute moderate to severe post operative pain to
generic Oxycodone/APAP(acetaminophen) (Percocet) 10mg/650mg by mouth every 6 hours.
An Open Label, Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP( Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain.
Completed
Lotus Clinical Research, LLC
Phase 4
2014-05-01
The purpose of this study is to compare the analgesic efficacy of Xartemis 15mg/650mg by
mouth every 12 hours for the management of acute moderate to severe post operative pain to
generic Oxycodone/APAP(acetaminophen) (Percocet) 10mg/650mg by mouth every 6 hours.
Pharmacokinetics (PK) and Safety Study of XARTEMIS® XR in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain
Terminated
Mallinckrodt
Phase 4
2015-11-20
Phase 4, multicenter, open-label, multiple-dose study of the pharmacokinetics (PK) and safety
of XARTEMIS XR in postsurgical adolescent subjects aged 12 to 17 years with moderate to
severe acute pain. The study will assess the safety of administering multiple doses of
XARTEMIS XR in this population.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
